Umhlahlandlela weziguli emisebenzini yokusetshenziswa kanye nemiphumela ye-Topical Fluorouracil
Ukwelashwa okuvamile kwe- basal cell carcinoma -uhlobo oluvame kakhulu lomdlavuza wesikhumba emhlabeni wonke-kuyinto yesikhumba (esetshenziswa esikhumbeni kuphela) ukhilimu, njenge-Efudex (i-fluorouracil). Uma udokotela wakho enqume u-Efudex, lesi singeniso sizokunika ulwazi oludinga ukuyisebenzisa ngokuphumelelayo nangokuphepha.
Qaphela ukuthi lolu lwazi lungase lumboze zonke izinyathelo zokuphepha, ukusebenzisana noma imiphumela emibi yalesi sidakamizwa. Uma unemibuzo mayelana nanoma imuphi umuthi oyithathayo, qiniseka ukuthi uhlole nomsebenzi wakho wezokwelapha.
Sibutsetelo
U-Efudex (amanye amagama omuthi afaka i-Carac ne-Fluoroplex) ukhilimu okwesibhakabhaka osetshenziselwa ukwelashwa kwe- basal cell carcinoma uma izindlela ezijwayelekile zingasebenzi, njengalezi zinkinga eziningi noma izindawo ezinzima zokwelapha ebusweni noma esikhwameni. Ibuye isetshenziselwe ukwelapha i- actinic keratosis (ebizwa nangokuthi i-solar keratosis), engabangela ukuba i- squamous cell carcinoma engapheli kakhulu uma ingashiywa ingaphathwa.
U-Efudex uyisidakamizwa se-chemotherapy (i-"antimetabolite") ephazamisa ukwakheka kwe-DNA ne-RNA, okubalulekile ekuhlukaneni kwesisindo nokukhula. Lokhu kuvinjelwa kubangela ukufa kokukhula kwamangqamuzana anomdlavuza okusheshayo, okuyinto ethatha ngaphezulu fluorouracil kunamaseli anempilo. Ngefomu layo elinamandla kakhulu lokujova, i-Fluorouracil nayo isetshenziselwa ukwelapha isifuba, isisu, isisu nesifo somdlavuza .
Ukuphumelela
Izinga lokuphumelela lokuphatha i- basal cell carcinoma nge-fluorouracil cishe ngamaphesenti angu-93, ngokususelwa ekuhloleni izilonda ezingu-113 ezigulini ezingama-54.
Kodwa-ke, ama-basal cell carcinomas ahlukile, angafinyeleleka kalula kufanele aphathwe ngokuhlinzwa kusukela ukuphumelela ngezilonda ezinjalo cishe amaphesenti angu-100. Ngokungafani nokuhlinzekwa, u-Efudex akanakwenzeka ukushiya izibazi noma ukuguqula unomphela isikhumba sesikhumba.
Ezinye izifundo manje zibheke ukuthi i-Efudex ukhilimu ephumelelayo kangakanani ezindaweni ezingekho ebusweni zomzimba, nokuthi u-fluorouracil uqhathaniswa kanjani ne- imiquimod (Aldara) ukhilimu kanye ne- cryosurgery .
Isibonelo, esifundweni esisodwa saseJalimane seziguli ezine- actinic keratosis , ukwelashwa kwe-imiquimod kwaholela ekuhlanzeni kangcono izilonda nemiphumela engcono yezimonyo uma kuqhathaniswa ne-cryosurgery ne-fluorouracil. Khuluma nodokotela wakho ngokuthi iyiphi imithi engcono kakhulu kuwe.
Ukusetshenziswa
Ku-basal cell carcinoma, kunconywa ukuba ama-5% amaphesenti e-fluorouracil asetshenziswe kabili ngosuku ngosuku olwanele ukumboza izilonda okungenani amaviki amathathu kuya ku-6. Ukwelashwa kungadingeka isikhathi eside uma sekuphele amasonto ayishumi kuya kwangu-12 ngaphambi kokuba izinhlungu ziphele. Ukufaka isicelo salolu mithi, sebenzisa umfakisicelo ophethwe ukotini, noma sebenzisa iglavu uma uyifaka ngesandla sakho. Uma kusetshenziselwa iminwe engavumelekile, kubalulekile ukugeza izandla zakho emva kokufaka isicelo salolu mithi. Gwema ukufaka isicelo emehlweni, ekhaleni, noma emlonyeni.
Okuqhamuka uma udla imishanguzo
Ngokuvamile, izindawo eziphathwayo zingase zingaboni kahle ngesikhathi sokukwelashwa, futhi ngokuvamile ziphele amasonto ambalwa ngemva kokuphela kokwelapha. Umphumela we-fluorouracil uvela ngezigaba ezine:
- Isigaba sokuqala sokuvuvukala: Phakathi nesonto lokuqala lesicelo, ukuvuvukala okuncane kwenzeka.
- Isigaba sokuvuvukala: Phakathi namasonto alandelayo, ubomvu nokuvuvukala kwenzeka nge-crusting nokushisa.
- I-tumor ukungena kwesigaba: Izilonda zixazulula njengoba isikhumba sidlula.
- Isigaba sokuphulukisa: Amasonto angaphezu kwangu-1 kuya kwangu-2, isikhumba esisha sikhula endaweni yonyango.
Imiphumela emibi ejwayelekile engadingi ukunakekelwa kwezokwelapha (kubika udokotela wakho noma uchwepheshe wezempilo ukunakekelwa uma beqhubeka noma bekhathazeka) kufaka:
- isikhumba esibomvu noma esimnyama
- ukuguguleka komzimba (ukulahlekelwa koqweqwe olungaphezulu kwesikhumba)
- ukucasuka kweso kufaka phakathi ukushisa, ukucheka, ukuzwela, ukugcoba, noma ukuchelela
- ukuzwela kakhudlwana kwesikhumba elangeni nokukhanya kwe-ultraviolet
- ubuhlungu nokushiswa kwendawo ethintekile
- ukoma, ukukala noma ukuvuvukala kwendawo ethintekile
- ukukhwabanisa isikhumba, ukushaywa kwendawo ethintekile
- ububele
Imiphumela emibi kakhulu okufanele uyibike kumdokotela wakho noma ochwepheshe bezempilo ngokushesha ngangokunokwenzeka ihlanganisa:
- ubuhlungu besisu
- isifo sohudo
- ukuhlanza
- umkhuhlane
- izikhukhula
Ukuqapha nokusebenzisana
I-efudex ukhilimu akufanele isetshenziswe ngabesifazane abakhulelwe, becabangela ukukhulelwa, noma ukunakekelwa ngoba kungalimaza ingane. Akufanele futhi isetshenziswe uma une-enzyme ye-dihydropyridine dehydrogenase (DPD), ngoba imiphumela emibi ingase iholele. I-DPD yisimo esiyinzalo esivela emaphesenti amathathu kuya ku-5 emaphesenti wabantu futhi sidinga ukuhlolwa kofuzo olukhethekile ukuxilonga. Ngaphezu kwalokho, tshela udokotela wakho uma:
- baphethwe ukwelashwa kwama-radiation
- bebelokhu benomphumela ongavamile noma we-allergyic ku-fluorouracil, ezinye i-chemotherapy, eminye imithi, ukudla, ama-dyes, noma ama-preservatives
Gwema ukukhanya kwelanga ngangokunokwenzeka ngenkathi usebenzisa u-Efudex ngoba kungakwandisa imiphumela yakho emibi. Uma ubonakale ekukhanyeni kwelanga, gqoka isigqoko futhi usebenzise isikrini selanga. Njengoba njalo, gwema futhi ukugwema amadokodo , okuye kwaxhunyaniswa ngokucacile ne-squamous cell carcinoma ne-melanoma.
Imithombo
- "I-Carac Yokubhala Ulwazi." sanofi- aventis US LLC.
- "U-Efudex Ukuchaza Ulwazi." I-Valeant Pharmaceuticals.
- U-Krawtchenko N, uRoewert-Huber J, Ulrich M, Mann I, uSterry W, Stockfleth E. "Ukuhlola okungahleliwe kwe-5% i-imiquimod ne-topical 5-fluorouracil ne-cryosurgery kuma-immunocompetent patients ane-actinic keratoses: ukufaniswa kwemitholampilo imiphumela ye-histological kuhlanganise nokulandela okungu-1. " Br J Dermatol . 157 Isondlo 2: 34-40.
- I-Newman MD, i-Weinberg JM. Imithi yokwelashwa ekhanda ekwelapheni i-actinic keratosis ne-basal cell carcinoma. I-Cutis . 79 (I-Suppl): 18-28.